Seven of ten FDA advisers said on Wednesday that the benefits of Grail’s Galleri blood test outweigh its risks. Two voted no and one abstained. No test of this kind has FDA approval today, so the vote moves a long-debated idea, one blood draw that hunts for dozens of cancers at once, a real step closer to routine medicine. The margins, though, say more than the headline does.
Start with what was not in doubt. All ten members of the Molecular and Clinical Genetics Devices Panel agreed there is reasonable assurance the Galleri blood test is safe. On whether it works, they split 6 to 4. On the overall balance of benefit and risk for adults 50 and older, the result was 7 to 2 with one abstention. These are recommendations. The FDA does not have to follow them, though it usually does, and it has not named a decision date.
What the Galleri blood test finds, and what it misses
Galleri looks for chemical patterns in fragments of DNA that tumours shed into the bloodstream, and when it spots a signal it also guesses which organ the cancer came from. In two large studies, the American PATHFINDER 2 and the NHS-Galleri trial in England, that guess was right more than 90% of the time. The strength of the test is how rarely it cries wolf. According to the FDA reviewers’ briefing document, false positives ran at 0.15% in the American study and 0.26% in the English one. When Galleri did flag someone, cancer was later confirmed in 77% of cases in PATHFINDER 2 and 66.2% in NHS-Galleri.
The weakness is what it lets through. Across cancers diagnosed within a year, Galleri caught 35.0% in the American study and 31.6% in the English one. Stage I cancers, the ones people most want caught, were found 21.4% and 13.6% of the time. Detection also swings by cancer type: roughly 80% for liver cancers, but 10.7% for prostate and between 19% and 26% for breast. A positive result usually means something. A negative one is not a clean bill of health.
Why the Galleri blood test split the panel on effectiveness
The missing piece is proof that any of this saves lives. No trial has yet shown that Galleri screening reduces cancer deaths. The NHS-Galleri trial did not meet its main goal, and while its first screening round showed 13% fewer stage IV diagnoses across 12 pre-selected cancers, no formal statistical test was run, so chance could explain the gap, according to a MedicalDaily review of the data.
FDA staff also asked the panel whether the evidence justifies calling Galleri an “early detection” test at all. NPR reported that the panel recommended keeping that word out of the marketing and telling patients to continue their routine screenings. Michelle Tarver, who leads the FDA’s device centre, called the concept promising but said a technology this new demands careful evaluation. Then there is the cost of being wrong. In PATHFINDER 2, 43 of the 90 people who got a false alarm ended up having at least one invasive procedure, and the median time to settle a case was 75 days. The FDA also warned that people with a negative result might put off standard screening.
What changes if the FDA agrees
The Galleri blood test is already on sale by prescription, but as a lab-developed test without FDA approval, and one analysis from MerlinTrader says its self-pay price limits uptake. Reuters has reported that approval is what brings physician guidelines and routine insurance coverage. The same MerlinTrader analysis points to a February 2026 US law that could let Medicare cover approved multi-cancer tests from 1 January 2029, starting with beneficiaries aged 50 to 65. Grail says it intends to pursue that route.
For the company, the stakes are plain. Grail reported $42.6 million in test revenue for the second quarter against a net loss of $110.2 million, and its shares jumped about 34% on Monday when the FDA’s briefing papers raised no major safety concerns. Trading was halted while the panel met. For anyone over 50 who is curious, the practical point is the one the panel itself pressed. The Galleri blood test is meant to be added to mammograms, colonoscopies and other recommended checks, not to replace them, and whether it fits a particular person is a question for their own doctor.
Which leaves the FDA with an awkward calculation. The test clearly finds some cancers. Whether finding them this way helps people live longer will take years to prove, and the agency now has to decide how much of that proof it will demand before letting the Galleri blood test onto the market, and how much afterwards.
[…] roughly three and a half hours the hospital confirmed the patient was no longer considered a potential case. The patient’s name, age, symptoms and condition […]